| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Vilazodone D8 targets the serotonin transporter (SERT) and the 5-HT1A receptor. As a deuterated form of Vilazodone, it retains the pharmacological profile of the parent compound: inhibition of serotonin reuptake and partial agonism at 5-HT1A receptors. This dual mechanism is believed to contribute to its antidepressant effects.
|
|---|---|
| ln Vitro |
In vitro, Vilazodone D8 is used as an internal standard for the quantification of Vilazodone by GC- or LC-MS. The deuterium label does not significantly alter the compound's pharmacological activity; therefore, it exhibits similar SSRI and 5-HT1A partial agonist properties as Vilazodone.
|
| ln Vivo |
In vivo, Vilazodone (the parent compound) is clinically approved for the treatment of major depressive disorder (MDD). Vilazodone D8 is not intended for therapeutic use but serves as an analytical standard for pharmacokinetic and bioanalytical studies.
|
| Enzyme Assay |
For in vitro receptor binding assays, Vilazodone D8 is evaluated using radioligand binding assays with SERT and 5-HT1A receptors. The compound is incubated with a radiolabeled ligand, and the displacement of binding is measured to determine affinity. As a deuterated analog, its binding affinity is expected to be similar to Vilazodone.
|
| Cell Assay |
For in vitro cellular assays, Vilazodone D8 is dissolved in DMSO and applied to cells expressing SERT or 5-HT1A receptors. Serotonin uptake inhibition is measured using radiolabeled serotonin, and 5-HT1A receptor agonism is assessed using functional assays such as GTPgammaS binding or cAMP accumulation.
|
| Animal Protocol |
In vivo animal studies with Vilazodone D8 are not typically performed, as the compound is used as an analytical standard. However, the parent compound Vilazodone has been studied in animal models of depression, including forced swim test and tail suspension test in rodents.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Vilazodone D8 are not available, as it is used as an internal standard rather than a therapeutic agent. Vilazodone (parent compound) is orally bioavailable and has well-characterized PK properties. The compound should be stored according to the manufacturer's recommendations.
|
| Toxicity/Toxicokinetics |
Toxicology data for Vilazodone D8 are not available. The parent compound Vilazodone is clinically approved for MDD and has a well-established safety profile. Vilazodone D8 is intended for research and analytical use only.
|
| Additional Infomation |
Vilazodone D8 (CAS#: 1794789-93-7) is a deuterium-labeled form of Vilazodone with the molecular formula C2₆H2₇N₅O2 (with deuterium substitution). It is used as an internal standard for the quantification of Vilazodone in biological samples by mass spectrometry. The compound is a research reagent only and is not approved for therapeutic use.
|
| Molecular Formula |
C26H27N5O2
|
|---|---|
| Molecular Weight |
441.524885416031
|
| Exact Mass |
449.266
|
| CAS # |
1794789-93-7
|
| Related CAS # |
Vilazodone Hydrochloride;163521-08-2;Vilazodone;163521-12-8
|
| PubChem CID |
71752924
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
745.1±60.0 °C at 760 mmHg
|
| Flash Point |
404.4±32.9 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.711
|
| LogP |
3.98
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
33
|
| Complexity |
729
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C1(C(N(C(C(N1CCCCC2=CNC3=C2C=C(C=C3)C#N)([2H])[2H])([2H])[2H])C4=CC5=C(C=C4)OC(=C5)C(=O)N)([2H])[2H])[2H]
|
| InChi Key |
SGEGOXDYSFKCPT-PMCMNDOISA-N
|
| InChi Code |
InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)/i9D2,10D2,11D2,12D2
|
| Chemical Name |
5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-2,2,3,3,5,5,6,6-octadeuteriopiperazin-1-yl]-1-benzofuran-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2649 mL | 11.3245 mL | 22.6490 mL | |
| 5 mM | 0.4530 mL | 2.2649 mL | 4.5298 mL | |
| 10 mM | 0.2265 mL | 1.1325 mL | 2.2649 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
